Oct 2026
ctDNA clearance and outcomes for resectable lung cancer from NeoCOAST-2.
L. McGrath, Gozde Kar, L. Bonanno et al.
· Nature · 0 citations
2 papers indexed here
We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.
Not the right person? Other researchers publish under this name.
Review
Open access
Oct 2026
Pembrolizumab with or without platinum-based chemotherapy as first-line treatment in advanced NSCLC expressing PD-L1 ≥50%: The PERSEE randomized phase III trial (GFPC 01-2020).
BACKGROUND Pembrolizumab, alone or combined with platinum-based chemotherapy, is a standard first-line treatment for patients with metastatic non-small-cell lung cancer (NSCLC) without actionable oncogenic alterations and with high programmed death-ligand 1 (PD-L1) expression. We conducted a head-to-head comparison of...
R. Descourt, A. Mogenet, Maelys Consigny et al.
· Annals of Oncology · 0 citations